Literature DB >> 30918343

Protective effects of specific cannabinoid receptor 2 agonist GW405833 on concanavalin A-induced acute liver injury in mice.

Ze-Bing Huang1,2, Yi-Xiang Zheng1,2, Ning Li3, Sheng-Lan Cai1,2, Yan Huang1,2, Juan Wang1,2, Xing-Wang Hu1,2, Yang Wang2,4, Jie Wu5,6, Xue-Gong Fan7,8.   

Abstract

Cannabinoid receptor 2 (CB2R) is highly expressed in immune cells and plays an important role in regulating immune responses. In the current study, we investigated the effects of GW405833 (GW), a specific CB2R agonist, on acute liver injury induced by concanavalin A (Con A). In animal experiments, acute liver injury was induced in mice by injection of Con A (20 mg/kg, i.v.). The mice were treated with GW (20 mg/kg, i.p., 30 min after Con A injection) or GW plus the selective CB2R antagonist AM630 (2 mg/kg, i.p., 15 min after Con A injection). We found that Con A caused severe acute liver injury evidenced by significantly increased serum aminotransferase levels, massive hepatocyte apoptosis, and necrosis, as well as lymphocyte infiltration in liver tissues. Treatment with GW significantly ameliorated Con A-induced pathological injury in liver tissue, decreased serum aminotransferase levels, and decreased hepatocyte apoptosis. The therapeutic effects of GW were prevented by AM630. In cell experiments, we showed that CB2Rs were highly expressed in Jurkat T cells, but little expression in L02 liver cells. Treatment with GW (10-40 μg/mL) dose-dependently decreased the viability of Jurkat T cells and induced cell apoptosis, which was reversed by AM630. In the coculture of Jurkat T cells with L02 liver cells, GW dose-dependently protected L02 cells from apoptosis induced by Con A (5 μg/mL). The protective effect of GW was reversed by AM630 (1 μg/mL). Our results suggest that GW protects against Con A-induced acute liver injury in mice by inhibiting Jurkat T-cell proliferation through the CB2Rs.

Entities:  

Keywords:  AM630; Concanavalin A; GW405833; Jurkat T cells; L02 liver cells; acute liver injury; cannabinoid receptor 2

Mesh:

Substances:

Year:  2019        PMID: 30918343      PMCID: PMC6888824          DOI: 10.1038/s41401-019-0213-0

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  1 in total

1.  The Effect of Nutritional Status on Outcome of Hospitalization in Paediatric Liver Disease Patients.

Authors:  Yasmeen Mansi; Shereen Abdel Ghaffar; Shaymaa Sayed; Hanaa El-Karaksy
Journal:  J Clin Diagn Res       Date:  2016-12-01
  1 in total
  5 in total

Review 1.  Nanophytomedicines for the Prevention of Metabolic Syndrome: A Pharmacological and Biopharmaceutical Review.

Authors:  Zeinab Nouri; Marziyeh Hajialyani; Zhila Izadi; Roodabeh Bahramsoltani; Mohammad Hosein Farzaei; Mohammad Abdollahi
Journal:  Front Bioeng Biotechnol       Date:  2020-05-14

Review 2.  Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products.

Authors:  Dongchen An; Steve Peigneur; Louise Antonia Hendrickx; Jan Tytgat
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

3.  Low Basal CB2R in Dopamine Neurons and Microglia Influences Cannabinoid Tetrad Effects.

Authors:  Qing-Rong Liu; Ana Canseco-Alba; Ying Liang; Hiroki Ishiguro; Emmanuel S Onaivi
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

4.  A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection In Vivo.

Authors:  Senthil Jayarajan; Joseph J Meissler; Martin W Adler; Toby K Eisenstein
Journal:  Front Pharmacol       Date:  2022-02-03       Impact factor: 5.810

5.  Expression and Functions of the CB2 Receptor in Human Leukocytes.

Authors:  Mélissa Simard; Volatiana Rakotoarivelo; Vincenzo Di Marzo; Nicolas Flamand
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.